Etripamil Nasal Spray Converts Recurrent PSVT After Ablation in RAPID Subgroup

Milestone Pharmaceuticals released data Saturday showing its nasal spray Cardamyst converted recurrent irregular heart rhythms in most patients who had already undergone catheter ablation, a finding the company says could give those patients a self-administered alternative to a repeat procedure or an emergency-room visit.

The subgroup analysis from the Phase 3 RAPID trial, presented at the American Heart Association Scientific Sessions in Chicago, looked at 11 patients with prior ablation who had confirmed recurrences of paroxysmal supraventricular tachycardia. Six of them received etripamil — the drug’s generic name — and four converted to normal sinus rhythm within 30 minutes, a 66.7% rate. One of five placebo patients converted, Cardiac Rhythm News reported.

“Most patients do well after ablation but a subset continues to have episodes, and we have had limited options to offer them for treating an episode outside of an emergency room setting.”

The overall RAPID trial, published in The Lancet in 2023, enrolled 692 patients across multiple centers. Before randomization, everyone received a test dose of etripamil 70 mg, then a second dose 10 minutes later to assess tolerability and train them on the device, HCPLive reported.

Patients were then assigned 1:1 to etripamil or placebo. In the full efficacy population of 184 patients with adjudicated, AV-nodal-dependent PSVT, Kaplan-Meier estimates showed a 64% conversion rate at 30 minutes with etripamil versus 31% with placebo.

Catheter ablation cures most PSVT, but a minority of patients — 6.6% of the randomized RAPID cohort, or 46 of 692 — had a documented prior ablation. Among the 184 patients with confirmed PSVT in the efficacy population, 11 (6%) had been ablated before. Those 11 patients, mean age 50.9 years and 82% female, form the subgroup analyzed here. Just over half were already taking oral AV-nodal blocking agents such as beta blockers or calcium channel blockers.

Safety monitoring in this subgroup used continuous ECG recordings and adverse-event reporting, with specific attention to AV block and prolonged pauses. The authors said they saw no distinct safety signals. Treatment-emergent adverse events occurred in 50% of etripamil recipients across the broader trial versus 11% on placebo, HCPLive noted.

David Bharucha, Milestone’s chief medical officer, framed the data as reinforcement for the broader label. “In this analysis from the RAPID trial, patients with recurrent PSVT after a prior ablation responded to etripamil in a manner consistent with the overall trial population,” he said in the company release.

“Thus, we believe these findings reinforce the overall data which show etripamil to be a safe and effective treatment option, and support this drug to be used as a self-administered treatment for patients who may have continued episodes of PSVT after ablation.”

The company and investigators were explicit: this subgroup analysis was not powered for statistical comparison. The numbers — six treated, five placebo — are descriptive.

Ip acknowledged the limitation in his comments: “These data, although from a small group, are encouraging, because the response to etripamil nasal spray in patients with a prior ablation is similar to what we observed across the broader RAPID population.” He added that for patients weighing a repeat ablation, “having a self-administered option to treat an episode should be a meaningful part of the conversation they have with their cardiologist.”

Cardamyst won FDA approval for the acute conversion of symptomatic PSVT episodes in adults. The RAPID trial (NCT03464019) was a randomized, double-blind, event-driven, placebo-controlled study evaluating a single or repeat 70 mg dose self-administered during a perceived episode, with a repeat dose permitted per protocol. Episodes were adjudicated from ambulatory ECG recordings.

The poster was presented Saturday, November 7, in a moderated session at AHA 2026.